All products are sold strictly for laboratory research use only. Not for human or veterinary consumption, diagnosis, or treatment. Not approved by the FDA.

Research Use Only

Search results for "CAS number"

Found 11 products

11 results

Sort by:

T -GLP-1 (15mg)

T -GLP-1 (15mg)

First-in-Class Dual GIP/GLP-1 Receptor Agonist: 39aa twincretin with imbalanced dual agonism favoring GIPR, biased GLP-1R signaling (cAMP > beta-arrestin), FDA-approved Mounjaro (T2D 2022)/Zepbound (obesity 2023), 3,000+ publications
Unprecedented Weight Loss Efficacy: SURMOUNT-1 (Jastreboff et al., 2022, NEJM): 22.5% mean body weight reduction at 72 weeks, 39.7% participants achieved ≥25% loss, SURMOUNT-5 superior to semaglutide
Clinical Status: SURPASS-CVOT cardiovascular non-inferiority vs dulaglutide with 16% lower all-cause mortality (HR 0.84), SUMMIT trial 38% reduction CV death/worsening HF in HFpEF+obesity (HR 0.62), SYNERGY-NASH 73.3% MASH resolution at 15mg

$129.00

Tirzepatide (15mg)

Tirzepatide (15mg)

Tirzepatide (LY3298176) is a first-in-class 39-amino acid dual GIP/GLP-1 receptor agonist ("twincretin") with imbalanced agonism favoring GIPR over GLP-1R
Features Aib residues at positions 2 and 13 (DPP-4 resistance), C20 fatty diacid at Lys20 (albumin binding, ~5-day half-life), and biased GLP-1R signaling favoring cAMP over beta-arrestin recruitment
FDA-approved as Mounjaro (T2D, May 2022) and Zepbound (obesity, Nov 2023)

$129.00

Tirzepatide (30mg)

Tirzepatide (30mg)

First-in-Class Dual GIP/GLP-1 Agonist: 39-amino acid synthetic peptide (LY3298176), Eli Lilly design, imbalanced dual agonism (GIPR>GLP-1R), biased GLP-1R signaling (cAMP>beta-arrestin), 3,000+ publications, ~5-day half-life via C20 fatty diacid albumin binding
Unprecedented Metabolic Effects: HbA1c reduction 1.24-2.58%, 22.5% mean weight loss at 15mg (SURMOUNT-1), weight-independent insulin sensitization via GIPR, BCAA catabolism, central appetite suppression
Clinical Status: FDA-approved Mounjaro (T2D, May 2022), Zepbound (obesity, Nov 2023), OSA (Dec 2024); SURPASS-CVOT 38% reduction CV death/HF events, SYNERGY-NASH 73.3% MASH resolution

$199.00

Reta (10mg)

Reta (10mg)

First-in-Class Triple Agonist: 39 aa peptide simultaneously activating GIPR (EC₅₀ 0.0643 nM), GLP-1R (EC₅₀ 0.775 nM), GCGR (EC₅₀ 5.79 nM), GIP backbone with Aib/C20 fatty diacid, t½ 6 days, once-weekly
Superior Efficacy: Phase 2 obesity 24.2% weight loss at 48 weeks (12 mg), MASLD 82.4% liver fat reduction, T2D HbA1c -2.02%, 100+ publications, 100% ≥5% weight loss responders
Clinical Development: Phase 3 TRIUMPH program (5,800+ participants), TRIUMPH-4 showed 26.4-28.7% weight loss at 68 weeks, TRANSCEND cardiovascular outcomes program, dose-dependent GI AEs

$0.00

Cagrilintide (10mg)

Cagrilintide (10mg)

Cagrilintide - Long-acting amylin analog activating AMY1R/AMY2R/AMY3R and CALCR receptors
≥98% purity (HPLC)
Half-life 159-195 hours

$99.00

Cagrilintide (5mg) / Tirz (10mg)

Cagrilintide (5mg) / Tirz (10mg)

Triple-Receptor Agonist: Combines amylin, GIP, and GLP-1 pathways in one formulation
Multi-Pathway Engagement: Three independent satiety and metabolic control mechanisms
Research Blend: 5mg Cagrilintide + 10mg Tirzepatide, ≥98% purity each component

$199.00

$149.00

Fragment 176-191 (5mg)

Fragment 176-191 (5mg)

HGH C-Terminal Fragment: 16-amino acid sequence (FLRIVQCRSVEGSCGF), ≥98% purity
β3-AR Pathway Modulation: DAG-PKC-HSL lipolytic cascade activation research
Selective Lipolysis Studies: GHR-independent fat metabolism without IGF-1 effects

$0.00

AOD9604 6mg

AOD9604 6mg

Synthetic hGH Fragment: 16-amino acid C-terminal peptide (177-191), ≥98% purity
Beta-3-AR Upregulation: Enhances lipolysis while suppressing lipogenesis without IGF-1 elevation
Metabolic Research: Six human trials (900+ participants), FDA GRAS status

$48.00

5-Amino-1MQ 50mg (60 Capsules)

5-Amino-1MQ 50mg (60 Capsules)

NNMT Inhibitor: Small-molecule inhibitor of nicotinamide N-methyltransferase (IC50 = 1.2 μM), ≥98% purity
NAD+ Salvage Enhancement: Preserves nicotinamide for NAD+ biosynthesis; elevates intracellular NAD+ by 1.2-1.6-fold
Metabolic Research: Studied in obesity, muscle aging, cardiovascular function, and neurodegenerative disease models

$99.00

BAM15 (15mg) 60 capsules

BAM15 (15mg) 60 capsules

Mitochondrial Uncoupler: Selective protonophore (C₁₆H₁₀F₂N₆O), ≥98% purity
AMPK Activation: 1,000-fold greater potency than metformin per unit concentration
Metabolic Research: 50+ publications since 2014, validated in Nature Communications

$99.00

SLU-PP-332 Capsules (250mcg) 100 Count

SLU-PP-332 Capsules (250mcg) 100 Count

Pan-ERR Agonist Exercise Mimetic: Hydrazone small molecule (E)-4-hydroxy-N'-(naphthalen-2-ylmethylene)benzohydrazide, Saint Louis University design, activates ERRalpha/beta/gamma (EC50 98/230/430 nM), 10+ publications, all preclinical
Multi-System Metabolic Reprogramming: 70% increased endurance, 12% body weight loss, mitochondrial biogenesis via PGC-1alpha/AMPK/TFAM cascade, type IIa muscle fiber conversion, 25% increased fatty acid oxidation, reverses age-related kidney dysfunction
Clinical Status: No human trials (as of Feb 2026), all data from mouse models, well-tolerated in 8-week studies, successor compound SLU-PP-915 with improved oral bioavailability developed 2026

$89.00